One Genomics Inc.
Creating a New Therapeutic Standard with Safeguard gRNA
One Genomics Inc. is a startup built on the groundbreaking "Safeguard gRNA" technology developed at Kyushu University, which enhances genome editing efficiency and safety by more than 100-fold. This platform precisely controls and finetunes the DNA editing activity of CRISPR/Cas systems, enabling safer and more efficient genome editing. With broad applicability to various genome editing tools, it has the potential to become the gold standard that significantly advances the practical implementation of gene therapy. This technology offers an innovative solution to the safety concerns that have emerged in clinical trials, promising the application of safe gene therapy.
- Establishment Date
- February 2023
- Business
- Safeguard gRNA Technology Development and Its Applications in Pharmaceutical Development
- CEO
- CEO Diana Luan
KII’s Perspective
One Genomics Inc.’s innovative genome editing technology has the potential to solve critical challenges in the practical application of gene and cell therapy. Widely applicable to current technologies, it is expected to be adopted as the gold standard in the medical field.
KII growth support
Financing assistance, Business strategy support, Business alliance support, Sales strategy planning support, Corporate function support, Public relations support, Research and development support
